Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Principal Investigator
Name
Paul Babyn
Degrees
M.D.,C.M.
Institution
University of Saskatchewan
Position Title
Professor and Physician Executive
Email
About this CDAS Project
Study
NLST (Learn more about this study)
Project ID
NLST-722
Initial CDAS Request Approval
Oct 22, 2020
Title
Development and cost analysis of a lung nodule management strategy combining artificial intelligence and Lung-RADS for baseline lung cancer screening
Summary
Artificial intelligence (AI) algorithms have demonstrated high accuracy for lung nodule classification, in some cases surpassing that of radiologists unaided by AI. However, it remains unclear how malignancy risk prediction scores from AI algorithms should be combined with and incorporated into current lung cancer screening management approaches such as Lung-RADS, and what the impact on healthcare utilization and cost may be. In this study, we will develop a lung nodule management strategy combining Lung-RADS with an AI malignancy risk score and determine the impact of this management strategy on follow-up investigations and associated costs in a baseline lung cancer screening population.
Aims

(1) Develop a lung nodule management strategy combining Lung-RADS and an AI risk score to refine categorization at the time of baseline lung cancer screening; and
(2) Determine the potential impact of this strategy on recommendations for further investigations following baseline screening and the associated costs of recommended follow-up investigations from a public payer perspective.

Collaborators

Scott J. Adams, MD, University of Saskatchewan